AFN-1252

DB12658InvestigationalSmall molecule

AFN-1252 has been used in trials studying the treatment of Cellulitis, Burn Infection, Wound Infection, Cutaneous Abscess, and Skin and Subcutaneous Tissue Bacterial Infections.

Mechanism: Pharmacologically active on Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI
Curator reviewed
Formula / weight: C₂₂H₂₁N₃O₃ · 375.428 g/mol (avg)
Code names: API-1252

Resolves to

Compound

UNIIT3O718IKKMCAS620175-39-5ChEMBLCHEMBL1652621PubChem10407120

Structure

InChIKeyQXTWSUQCXCWEHF-JXMROGBWSA-NSMILESCN(CC1=C(C)C2=CC=CC=C2O1)C(=O)\C=C\C1=CC2=C(NC(=O)CC2)N=C1

Targets

Q6GI75fabI

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with AFN-1252, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account